5th December 2017, Oxfordshire, UK. Sense Biodetection Limited (Sense) has today announced that it has opened a new development facility near Cambridge, UK. The new site will serve as the home to the company’s design, development and production activities under the leadership of Chief Development Officer, Ralph Lamble. The facility complements Sense’s existing molecular laboratory facilities near Oxford, UK, and provides the company with the infrastructure necessary to develop and commercialise its highly innovative clinical diagnostic products.
Ralph Lamble, CDO, commented, “this exciting expansion enhances our operational capabilities for successful product development and firmly embeds Sense within the network of the UK’s two leading University cities, with unrivalled access to the expertise and talent needed to support the Company’s future growth.”
About Sense: Sense Biodetection Limited is a molecular diagnostics company focused on improving healthcare decisions and processes by developing novel, user-centred tests in the fields of infections and oncology. The company is focussed on handheld tests to bring molecular diagnostics to the point-of-care, rather than complex instruments operated by trained users in central labs, which are the mainstay of the molecular diagnostics field.
Contact for Media Enquiries: firstname.lastname@example.org